Partnership with Carnot Institute Curie Cancer and BIODERMA for the global care of patients and their quality of life

<h5> A common goal: the global care of patients and their quality of life</h5> <p> The treatments against cancer very often cause effects on the skin: dry skin, burns ... These skin effects have a real impact on the lives of patients and may affect on their management, or even lead oncologists to reduce or suspend the treatment administered. This new area, which opens in the heart of Institut Curie's day hospital, will provide the care and treatment needed to reduce these skin toxicities. It will be a place of support and listening for patients who will find the necessary advice to take care of their skin and limit side effects</p> <p> Thanks to numerous measuring tools able to evaluate the state of the skin before and during the treatment (measurement of inflammation, skin thickness, hydration rate ...), the equipment put in place in the Area for Care and Skin Study will collect biological data in addition to clinical data and have a global vision of adverse effects of treatments on the skin. With collections of data to the hearts of patients, it will be possible to better understand how they experience these side effects. </p> <h5> A long-standing collaboration that is enriching</h5> <p> BIODERMA and Institut Curie (Carnot Insitute Curie Cancer) joined together in 2015 under the leadership of Isabelle Fromantin, Nurse-researcher at the Institut Curie, a specialist in oncology wounds. For 4 years, the BIODERMA Laboratory has been working for the prevention of cutaneous side effects by providing hygiene and care products as well as information brochures to educate patients.</p> <p> <em>"The signing of the partnership between Institut Curie and Naos / BIODERMA marks an important step in the development of partnership research within the Institut Curie. Nursing research and its applications in the Cosmetics and Medical Devices sector are areas of strong interest on the part of teams and for which there are major expectations of patients and their families. <strong>The Carnot Curie Cancer label was crucial in the conclusion of this agreement by supporting the teams towards the implementation of the contract including funding granted to the project team</strong> " s</em>ays Amaury Martin, Director of Technology Transfer and Industrial Partnerships Office and Director of the Carnot Curie Cancer.</p>